OncoSec just filed an S-1 with the SEC to issue shares so that they pay Inovio $6.4 million dollars they owe for purchase of certain non-DNA vaccine technology and intellectual property relating to selective tumor ablation technologies
Oncosec bought the technology from INO for $3m in March 2011 with 2 payments still remaining....$1m due in March 2013 & $1m due in Dec 2013. The $6.4m you refer to is the amount of money Oncosec says they need to fund their operations (including payments to INO) through 7/31/13
This is copied from the ONCS filing... The entire filing can be found on the OncoSec web site:
Investors, SEC Filing:
We expect to use the proceeds received from the offering for payment of amounts due to Inovio in accordance with the Asset Purchase Agreement with Inovio, to fund our clinical trials, and for working capital and general corporate purposes. See “Use of Proceeds” for more information.